Bo Reese

Bo Reese

Auto-generated profile, based on publicly available information

Bo Reese

Institute for Systems Genomics, Center for Genome Innovation, University of Connecticut, Storrs (B.R.).

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Science Advances
Verified
Journal Article
Open access
ACAshok Cheemala
Ashok Cheemala
AKAmy L. Kimble
Amy L. Kimble
EBEmily N. Burrage
Emily N. Burrage
SHStephen B. Helming
Stephen B. Helming
JTJordan D. Tyburski
Jordan D. Tyburski
PMPatrick A. Murphy
Patrick A. Murphy
Mutations in the TARDBP gene encoding TDP-43 protein are linked to loss of function in neurons and familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We recently identified reduced nuclear TDP-43 in capillary endothelial cells (ECs) of donors with ALS-FTD. Because blood-brain barrier (BBB) permeability increases in ALS-FTD, we postulated that reduced nuclear TDP-43 in ECs might contribute. Here, we show that nuclear TDP-43 is reduced in ECs of mice with an ALS-FTD–associated mutation in TDP-43 ( Tardbp G348C ) and that this leads to cell-autonomous loss of junctional complexes and BBB integrity. Targeted excision of TDP-43 in brain ECs recapitulates BBB defects and loss of junctional complexes and ultimately leads to fibrin deposition, gliosis, phospho-Tau accumulation, and impaired memory and social interaction. Transcriptional changes in TDP-43–deficient ECs resemble diseased brain ECs. These data show that nuclear loss of TDP-43 in brain ECs disrupts the BBB and causes hallmarks of FTD.

14 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAshok Cheemala
Ashok Cheemala
AKAmy L. Kimble
Amy L. Kimble
JTJordan D. Tyburski
Jordan D. Tyburski
NLNathan K. Leclair
Nathan K. Leclair
AZAamir Rafiq Zuberi
Aamir Rafiq Zuberi
PMPatrick A. Murphy
Patrick A. Murphy
Loss of nuclear TDP-43 occurs in a wide range of neurodegenerative diseases, and specific mutations in the TARDBP gene that encodes the protein are linked to familial Frontal Temporal Lobar Dementia (FTD), and Amyotrophic Lateral Sclerosis (ALS). Although the focus has been on neuronal cell dysfunction caused by TDP-43 variants, TARDBP mRNA transcripts are expressed at similar levels in brain endothelial cells (ECs). Since increased permeability across the blood brain barrier (BBB) precedes cognitive decline, we postulated that altered functions of TDP-43 in ECs contributes to BBB dysfunction in neurodegenerative disease. To test this hypothesis, we examined EC function and BBB properties in mice with either knock-in mutations found in ALS/FTLD patients ( TARDBP G348C and GRN R493X ) or EC-specific deletion of TDP-43 throughout the endothelium ( Cdh5(PAC)CreERT2; Tardbp ff ) or restricted to brain endothelium ( Slco1c1(BAC)CreERT2; Tardbp ff ). We found that TARDBP G348C mice exhibited increased permeability to 3kDa Texas Red dextran and NHS-biotin, relative to their littermate controls, which could be recapitulated in cultured brain ECs from these mice. Nuclear levels of TDP-43 were reduced in vitro and in vivo in ECs from TARDBP G348C mice. This coincided with a reduction in junctional proteins VE-cadherin, claudin-5 and ZO-1 in isolated ECs, supporting a cell autonomous effect on barrier function through a loss of nuclear TDP-43. We further examined two models of Tardbp deletion in ECs, and found that the loss of TDP-43 throughout the endothelium led to systemic endothelial activation and permeability. Deletion specifically within the brain endothelium acutely increased BBB permeability, and eventually led to hallmarks of FTD, including fibrin deposition, microglial and astrocyte activation, and behavioral defects. Together, these data show that TDP-43 dysfunction specifically within brain ECs would contribute to the BBB defects observed early in the progression of ALS/FTLD.

25 June 2021 in Nursing Research
Verified
Journal Article
Closed access
SCSharon G. Casavant
Sharon G. Casavant
HLHongfei Li
Hongfei Li
BRBo Reese
Bo Reese
MCMing-Hui Chen
Ming-Hui Chen
Xiaomei CongXiaomei Cong
Xiaomei Cong
Background: Annually, approximately 15 million babies are born preterm (<37 weeks gestational age) globally. In the neonatal intensive care unit (NICU) environment, infants are exposed to repeated stressful or painful procedures as part of routine lifesaving care. These procedures have been associated with epigenetic alterations that may lead to an increased risk of neurodevelopmental disorders. Telomere length has been negatively associated with adverse life experiences in studies of adults. Objectives: This pilot study aimed to describe telomere length in a sample of preterm infants at NICU discharge and examine any associations with pain, feeding method, and neurodevelopment. Methods: This descriptive pilot study sample includes baseline absolute telomere length (aTL) of 36 preterm infants immediately prior to discharge. Quantitative polymerase chain reaction was used to determine aTL. Infant demographics, pain/stress, type of feeding, antibiotic use, neurodevelopment, and buccal swab data were collected. Descriptive data analysis was used to describe the telomere length using graphs. Results: Among our preterm infant samples, the mean aTL was far greater than the average adult telomere length. Although no significant associations were found between aTL and pain, feeding method, and neurodevelopment, a trend between sex was noted where male telomere lengths were shorter than females as they aged. Discussion: This is one of few studies to evaluate preterm infant telomere length. Although other researchers have used relative telomere length, we used the more accurate aTL. We found nonsignificant shorter telomere lengths among males. Additional large-scale, longitudinal studies are needed to better identify the predictors of telomere length at the time of discharge from NICU.

1 June 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
SNSarah-Anne E. Nicholas
Sarah-Anne E. Nicholas
SHStephen B. Helming
Stephen B. Helming
AMAntoine Ménoret
Antoine Ménoret
CPChristopher L. Pathoulas
Christopher L. Pathoulas
MXMaria M. Xu
Maria M. Xu
PMPatrick A. Murphy
Patrick A. Murphy
BACKGROUND: Atherosclerotic plaques form through lipid and immune cell accumulation beneath the arterial endothelium. CD8 (cluster of differentiation 8) T cells are abundant in lesions, and their activation correlates with cardiovascular disease severity. Although endothelial cells recruit CD8 T cells to low and disturbed flow regions, whether they regulate CD8 activation and persistence is unknown. These interactions may be mediated by posttranscriptional control of mRNA translation. METHODS: We used ribosomal profiling in Cdh5(PAC ); RiboTRAP mice to assess posttranscriptional regulation in atherosclerotic endothelium in a partial carotid ligation model. We then used CreERT2; Elavl ff; RiboTRAP (endothelial cell–knockout) mice to examine the impact of endothelial Elavl1 (ELAV-like RNA-binding protein 1) on gene expression programs and immune cell activity. RESULTS: Elavl1 motifs were enriched near alternative splicing events, and within 5′ untranslated regions of transcripts with altered ribosomal association in atherosclerosis. Elavl1 suppressed gene expression programs occurring in atherogenic endothelium, as deletion enhanced these responses and reduced CD8 T-cell accumulation (≈70%) at plaques without affecting recruitment, consistent with impaired persistence. In vitro, Elavl1-deficient endothelial cells suppressed antigen-dependent CD8 T-cell persistence, even in the presence of wild-type myeloid antigen-presenting cells and cognate antigen. CONCLUSIONS: Endothelial Elavl1 suppression enables endothelial cells to function as local immune checkpoint–like regulators of CD8 T-cell persistence in atherosclerosis. Thus, endothelial Elavl1 is a key regulator of adaptive immunity.

14 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
OOOmar M.F. Omar
Omar M.F. Omar
AKAmy L. Kimble
Amy L. Kimble
ACAshok Cheemala
Ashok Cheemala
JTJordan D. Tyburski
Jordan D. Tyburski
SPSwati Pandey
Swati Pandey
PMPatrick A. Murphy
Patrick A. Murphy
: Despite the importance of the endothelium in the regulation of the blood brain barrier (BBB) in aging and neurodegenerative disease, difficulties in extracting endothelial cell (EC) nuclei have limited analysis of these cells. In addition, nearly all Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD), and a large portion of Alzheimer’s Disease (AD) exhibit neuronal TDP-43 aggregation, leading to loss of nuclear function, but whether TDP-43 is similarly altered in human BBB ECs is unknown. Here we utilize a novel technique for the enrichment of endothelial and microglial nuclei from human cortical brain tissues, combined with inCITE-seq, to analyze nuclear proteins and RNA transcripts in a large cohort of healthy and diseased donors. Our findings reveal a unique transcriptional signature in nearly half of the capillary endothelial cells across neurodegenerative states, characterized by reduced levels of nuclear β-Catenin and canonical downstream genes, and an increase in TNF/NF-kB target genes. We demonstrate that this does not correlate with increased nuclear p65/NF-kB, but rather a specific loss of nuclear TDP-43 in these disease associated ECs. Comparative analysis in animal models with targeted disruption of TDP-43 shows that this is sufficient to drive these transcriptional alterations. This work reveals that TDP-43 is a critical governor of the transcriptional output from nuclear p65/NF-kB, which has paradoxical roles in barrier maintenance and also barrier compromising inflammatory responses, and suggests that disease specific loss in ECs contributes to BBB defects observed in the progression of AD, ALS and FTD.